Abstract: The present invention relates to a method for treating a disease or condition for which treatment involves the promotion of growth of neuronal cell processes and whose therapy comprises the administration of an agonist for neuronal cell surface receptors that promote outgrowth of neuronal processes said method comprising administering a therapeutically effective amount of said agonist in combination with a therapeutically effective concentration of one or more antioxidants/free radical scavengers and/or an agent capable of raising intracellular thiol levels and/or a steroid. A representative intracellular thiol is glutathione, the agent capable of raising intracellular thiol levels is N-acetylcysteine (NAC), and representative antioxidantsfree radical scavengers may be selected from the group consisting of Vitamin C, Vitamin E, analogs thereof and mixtures thereof. A representative Vitamin E analog is trolox.

Abstract: The provision of cell lines from virtually any cell type of the animal body is greatly facilitated by transgenic non-human eukaryotic animals of the invention in which at least some cells have (i) a differentiation inhibiting sequence chromosomally incorporated under the control of a non-constitutive promotor and/or (ii) a differentiation inhibiting sequence which is itself conditionally active. Said genes are chromosomally incorporated under the control of a promotor such that expression of said sequence is normally held below an effective level, thus allowing normal cell development. However, cells taken from said animal may be prevented from completing differentiation to a non-dividing state in tissue culture by activating expression of said sequence.

Abstract: The invention is directed to therapeutic methods for treating diseases associated with tumour necrosis factor-alpha (TNF-.alpha.) induced cell toxicity and/or complement induced cell toxicity, and improved methods for treating diseases whose therapy comprises the administration of n-acetylcysteine.

Abstract: The invention is directed to therapeutic methods for treating diseases associated with tumor necrosis factor-alpha (TNF-.alpha.) induced cell toxicity and/or complement induced cell toxicity, improved methods for treating diseases whose therapy comprises the administration of at least one growth factor, and improved methods for preventing cell death associated with acute tissue injury.

Abstract: The provision of cell lines from virtually any cell type of the animal body is greatly facilitated by transgenic non-human eukaryotic animals of the invention in which at least some cells have (i) a differentiation inhibiting sequence chromosomally incorporated under the control of a non-constitutive promotor and/or (ii) a differentiation inhibiting sequence which is itself conditionally active. Said genes are chromosomally incorporated under the control of a promotor such that expression of said sequence is normally held below an effective level, thus allowing normal cell development. However, cells taken from said animal may be prevented from completing differentiation to a non-dividing state in tissue culture by activating expression of said sequence.